Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012
Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Possible impact of serum IgE variability on dose calculation of omalizumab (anti-IgE) Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Correlation of changes of IgE with skin reactivity and clinical outcome during specific immunotherapy against home dust in asthmatic subjects Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Correlation between specific serum IgE and exhaled NO levels at low and high inhaled corticosteroid use in allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005
Returning asthma symptoms correlate with free IgE upon omalizumab cessation Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007
Investigation of gene expression in relation to omalizumab treatment and peanut oral immunotherapy Source: Virtual Congress 2021 – Biomarkers and risk factors in childhood asthma Year: 2021
Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow? Source: Annual Congress 2011 - Asthma management and response Year: 2011
Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma Source: Eur Respir J, 54 (5) 1900068; 10.1183/13993003.00068-2019 Year: 2019
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001
Pulmonary immunoglobulin E levels and the response to anti-immunoglobulin E antibody therapy in paediatric severe therapy resistant asthma Source: Annual Congress 2012 - Treating childhood asthma Year: 2012
Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018
Correlation between grass pollen specific IgG,IgG4 and IgE in patients treated with SIT Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002